Company: BOLT
Filing Date: 2025-03-24
Form Type: 10-K
Source: 0000950170-25-043873
Chunk: 136

Company: Bolt Biotherapeutics, Inc.
Filing Date: 2025-03-24
Form: 10-K
Item: Item 1B
Chunk 136
---
 will be secured, if at all, and to what degree such arrangements would affect our development plans and capital requirements. 

Our future clinical development costs may vary significantly based on factors such as: 

•the number and scope of preclinical and IND-enabling studies; 

•per-patient trial costs; 

•the number of trials required for approval; 

•the number of sites included in the trials; 

•the countries in which the trials are conducted; 

•the length of time required to enroll eligible patients; 

•the number of patients who participate in the trials; 

•the number of doses that patients receive; 

•the drop-out or discontinuation rates of patients; 

•potential additional safety monitoring requested by regulatory agencies; 

•the duration of patient participation in the trials and through all follow-up; 

•the cost and timing of manufacturing our product candidates; 

76

•the phase of development of our product candidates; and 

•the safety and efficacy profile of our product candidates. 

General and Administrative 

General and administrative expenses consist primarily of salaries and employee-related costs, including stock-based compensation, for personnel in executive, finance, and other administrative functions. Other significant costs include legal fees relating to intellectual property and corporate matters, professional fees for accounting and consulting services, and facility-related costs.  

We expect to continue to incur general and administrative expenses for the foreseeable future to support our ongoing research and development activities and the costs of operating as a public company. These costs will likely include expenses related to audit, legal, regulatory, and tax-related services associated with maintaining compliance with Nasdaq and SEC requirements, director and officer insurance premiums and investor relations costs associated with operating as a public company. 

Restructuring Charges 

Restructuring charges consist of one-time termination benefits such as severance costs and related benefits and stock-based compensation charges associated with a reduction-in-force. 

Impairment Charges

Impairment charges consist of one-time impairment loss associated with an impairment evaluation to assess the impact on the carrying value of our long-lived assets. 

Other Income, Net 

Interest Income, Net 

Interest income consists of interest income from our marketable securities investments.  

Other Income

Other income in 2024 consists of the one-time payment received from Innovent under the Amended Innovent Agreement. 

77

Results of Operations 

Comparison of the Years Ended December 31, 2024 and 2023 

    Years Ended December 31,

    2024

    2023